

Saskatchewan Immunization Manual Amendments 2023-09-25

Instructions: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

Chapter 7 Immunization of Special Populations

- Page 21 section 5.1 MSM
 - Mpox vaccine added.
- Page 35 Appendix 7.1
 - Mpox added to MSM
- Page 41 Appendix 7.6 HSCT Recipients
 - **New footnote!** ☹ - ALL previously immunized or unimmunized patients – First XBB.1.5 dose 4 month post-transplant and second XBB.1.5 dose 3 months later (or 6 months later after COVID-19 infection).
 - Footnote 1 addition: High dose flu vaccine is publicly funded only for those 65 years and older.
 - Footnote updated to refer to Ch. 7 referral forms (Appendices 7.2 & 7.3).
 - Footnote 11 updated to: Refer to SIM Appendix 7.4 High Dose Hepatitis B Immunization Algorithm - Renal, HIV, Congenital Immunodeficiency Client. Repeat series if response is less than 10 IU/mL after series completion.
- Page 44 Appendix 7.9 SOT Candidates
 - **New addition to table and new footnote for COVID-19 XBB.1.5 vaccine!** ☹ Unvaccinated pre-transplant SOT candidates should receive 3 doses (0-4 weeks-8 weeks) of mRNA vaccine as a primary series, with the final dose given 1-2 weeks prior to transplantation whenever possible. Subsequent boosters should be given 3 months later.
- Page 45 Appendix 7.10 SOT recipients
 - **New addition to table and new footnote for COVID-19 XBB.1.5 vaccine!** ☹ Unvaccinated pre-transplant SOT recipients should receive 3 doses (0-4 weeks-8 weeks) of mRNA vaccine as a primary series. Subsequent boosters should be given 3 months later. Vaccinated SOT recipients should receive booster doses 3 months after their previous vaccine dose. All SOT recipients should wait at least 1-month post-transplant to continue vaccine series, regardless of induction therapy. SOT recipients undergoing active treatment for acute rejection should defer vaccination for 1 month. SOT recipients with previous COVID-19 infection should defer vaccination for 3 months post-infection. SOT recipients who have received monoclonal antibodies for COVID-19 disease should defer vaccination for at least 90 days after therapy.

Chapter 10 Biological Products

- TOC first page
 - **New!** XBB.1.5 COVID-19 Vaccine Schedules
 - **New!** MODERNA Spikevax™ XBB.1.5 formulation 6+ months (0.1mg/ml; **Royal Blue Cap/Coral Blue Label**)
- COVID-19 Vaccine Q &A for Immunizers
 - Totally revised to address scenarios and questions related to XBB.1.5 vaccines. Ensure immunizers are familiar with the new content.
 - This section will be enhanced as other XBB.1.5 vaccines are licensed by Health Canada.
- **New!** XBB.1.5 COVID-19 Vaccine Schedules
 - Ensure immunizers are familiar with the new content.
 - Contains tables to address 5-11 and 12+ immune competent and immunocompromised individuals; children transitioning from 4 years to 5 years of age; and children presenting at 6 mo-4 years who are immune competent or immune compromised.

Saskatchewan Immunization Manual Amendments

2023-09-25

- This section will be enhanced as other XBB.1.5 vaccines are licensed by Health Canada.
- **New!** [MODERNA Spikevax™ XBB.1.5 formulation 6+ months \(0.1mg/ml; Royal Blue Cap/Coral Blue Label\)](#)
 - Scheduling and dosages for this vaccine are noted in [XBB.1.5 COVID-19 Vaccine Schedules](#).